OPTIMISE

OPtimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE)

 Coordinatore UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

 Organization address address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX

contact info
Titolo: Ms.
Nome: Mirjam
Cognome: Lormans
Email: send email
Telefono: -7944
Fax: -6255

 Nazionalità Coordinatore Netherlands [NL]
 Sito del progetto http://www.optimisetrial.eu/
 Totale costo 14˙900˙190 €
 EC contributo 11˙187˙685 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2009-single-stage
 Funding Scheme CP-IP
 Anno di inizio 2010
 Periodo (anno-mese-giorno) 2010-02-01   -   2016-07-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT

 Organization address address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX

contact info
Titolo: Ms.
Nome: Mirjam
Cognome: Lormans
Email: send email
Telefono: -7944
Fax: -6255

NL (UTRECHT) coordinator 3˙205˙464.06
2    KING'S COLLEGE LONDON

 Organization address address: Strand
city: LONDON
postcode: WC2R 2LS

contact info
Titolo: Mrs.
Nome: Silke
Cognome: Blohm
Email: send email
Telefono: +44 (0) 20 7848 0121.
Fax: +44 020 7848 0671

UK (LONDON) participant 1˙725˙194.26
3    ZENTRALINSTITUT FUER SEELISCHE GESUNDHEIT

 Organization address address: Square J 5
city: MANNHEIM
postcode: 68159

contact info
Nome: Simone
Cognome: Fuchs
Email: send email
Telefono: +49 621 1703 1321
Fax: +49 621 1703 2915

DE (MANNHEIM) participant 970˙695.00
4    SERVICIO MADRILENO DE SALUD

 Organization address address: PLAZA CARLOS TRIAS BERTRAN 7
city: MADRID
postcode: 28020

contact info
Titolo: Dr.
Nome: Albino
Cognome: Navarro
Email: send email
Telefono: +34 91 426 51 15
Fax: +34 91 400 81 56

ES (MADRID) participant 742˙961.28
5    REGION HOVEDSTADEN

 Organization address address: KONGENS VAENGE 2
city: HILLEROD
postcode: 3400

contact info
Titolo: Prof.
Nome: Birte
Cognome: Glenthøj
Email: send email
Telefono: +45 43233431

DK (HILLEROD) participant 714˙003.64
6    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)

 Organization address address: 101 Rue de Tolbiac
city: PARIS
postcode: 75654

contact info
Titolo: Mr.
Nome: Didier
Cognome: Lemoine
Email: send email
Telefono: 33145170315
Fax: 33148995407

FR (PARIS) participant 591˙356.36
7    KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN

 Organization address address: ISMANINGER STRASSE 22
city: MUENCHEN
postcode: 81675

contact info
Nome: Renate
Cognome: Rädlein
Email: send email
Telefono: +49 89 4140 2842
Fax: +49 89 4140 4926

DE (MUENCHEN) participant 450˙136.00
8    TANGENT DATA SRL

 Organization address address: CALEA VICTORIEI 91-93 SC C ET P AP
city: BUCURESTI
postcode: 10091

contact info
Titolo: Mr.
Nome: Rodica
Cognome: Gonen
Email: send email
Telefono: +40 723 586675
Fax: +40 21 2128105

RO (BUCURESTI) participant 446˙620.20
9    THE UNIVERSITY OF MANCHESTER

 Organization address address: OXFORD ROAD
city: MANCHESTER
postcode: M13 9PL

contact info
Titolo: Ms.
Nome: Liz
Cognome: Fay
Email: send email
Telefono: 441613000000
Fax: +44 161 275 2445

UK (MANCHESTER) participant 408˙047.00
10    Nome Ente NON disponibile

 Organization address address: VIALE BENEDUCE 10
city: CASERTA
postcode: 81100

contact info
Titolo: Ms.
Nome: Luciana
Cognome: Taliento
Email: send email
Telefono: -5666545
Fax: -5666565

IT (CASERTA) participant 234˙899.76
11    MEDICAL RESEARCH INFRASTRUCTURE DEVELOPMENT AND HEALTH SERVICES FUND BY THE SHEBA MEDICAL CENTER

 Organization address address: TEL HASHOMER SHEBA MEDICAL CENTER
city: RAMAT GAN
postcode: 52621

contact info
Titolo: Prof.
Nome: Michael
Cognome: Davidson
Email: send email
Telefono: 972527000000
Fax: na

IL (RAMAT GAN) participant 224˙072.95
12    Fondation FondaMental

 Organization address address: "Rue de Mesly, Hopital Chenevier, Pole de Psychiatrie 40"
city: Creteil
postcode: 94000

contact info
Nome: Maria
Cognome: Chovet
Email: send email
Telefono: +33 1 49 81 34 30

FR (Creteil) participant 215˙537.23
13    Clienia Schloessli AG

 Organization address city: Oetwil am See
postcode: 8618

contact info
Titolo: Dr.
Nome: Gregor
Cognome: Berger
Email: send email
Telefono: +41 (0)44 929 81 11
Fax: +41 44 929 84 50

CH (Oetwil am See) participant 214˙537.80
14    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH

 Organization address address: Ingolstaedter Landstrasse 1
city: MUENCHEN
postcode: 85764

contact info
Titolo: Dr.
Nome: Juergen
Cognome: Ertel
Email: send email
Telefono: -6249
Fax: -7093

DE (MUENCHEN) participant 213˙204.00
15    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN

 Organization address address: GESCHWISTER SCHOLL PLATZ 1
city: MUENCHEN
postcode: 80539

contact info
Titolo: Mr.
Nome: Alexander
Cognome: Vogl
Email: send email
Telefono: -5925
Fax: -5938

DE (MUENCHEN) participant 200˙319.90
16    UNIWERSYTET MEDYCZNY IM KAROLA MARCINKOWSKIEGO W POZNANIU

 Organization address address: Ul. Fredry 10
city: POZNAN
postcode: 61 701

contact info
Titolo: Prof.
Nome: Janusz
Cognome: Rybakowski
Email: send email
Telefono: 48600321411
Fax: na

PL (POZNAN) participant 175˙846.80
17    UNIVERZITA KARLOVA V PRAZE

 Organization address address: Ovocny trh 5
city: PRAHA 1
postcode: 11636

contact info
Titolo: Ms.
Nome: Eva
Cognome: Macourkova
Email: send email
Telefono: +420 495 816 136
Fax: +420 495 513 597

CZ (PRAHA 1) participant 103˙949.44
18    SPETSIALIZIRANA BOLNITSA ZA AKTIVNO LECHENIE PO NEVROLOGIA I PSIHIATRIA SV NAUM AD

 Organization address address: TSARIGRADSKO SHOSSE BULEVARD IV KILOMETER
city: SOFIA
postcode: 1113

contact info
Nome: Luchezar
Cognome: Hranov
Email: send email
Telefono: 35929702230

BG (SOFIA) participant 92˙376.80
19    MEDIZINISCHE UNIVERSITAET INNSBRUCK

 Organization address address: Christoph-Probst Platz 1
city: INNSBRUCK
postcode: 6020

contact info
Titolo: Dr.
Nome: Peter
Cognome: Josten
Email: send email
Telefono: +43 512 9003 70070
Fax: +43 512 9003 73001

AT (INNSBRUCK) participant 78˙705.36
20    MARTIN-LUTHER-UNIVERSITAET HALLE-WITTENBERG

 Organization address address: UNIVERSITAETSPLATZ 10
city: HALLE (Saale)
postcode: 6099

contact info
Titolo: Prof.
Nome: Dan
Cognome: Rujescu
Email: send email
Telefono: +49 3455573651

DE (HALLE (Saale)) participant 71˙900.40
21    UNIVERSITAETSKLINIKUM HEIDELBERG

 Organization address address: IM NEUENHEIMER FELD 672
city: HEIDELBERG
postcode: 69120

contact info
Titolo: Mr.
Nome: Thorsten
Cognome: Brietz
Email: send email
Telefono: +49 6221 567086
Fax: +49 6221 565460

DE (HEIDELBERG) participant 71˙900.40
22    KATHOLIEKE UNIVERSITEIT LEUVEN

 Organization address address: Oude Markt 13
city: LEUVEN
postcode: 3000

contact info
Titolo: Dr.
Nome: Elke
Cognome: Lammertyn
Email: send email
Telefono: +32 16 32 06 21
Fax: +32 16 326515

BE (LEUVEN) participant 22˙784.38
23    PSYCHIATRICKE CENTRUM PRAHA

 Organization address address: Ustavni 91
city: PRAHA
postcode: 18103

contact info
Titolo: Mr.
Nome: Alexandr
Cognome: Borovi?ka
Email: send email
Telefono: +420 266 003 400
Fax: +420 266 003 420

CZ (PRAHA) participant 13˙172.40

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

choice    mri    clinical    determine    evidence    drug    optimization    imaging    therapeutic    optimise    strategies    experimental    trials    markers    deficits    explore    genetic    goals    taken    treatments    cannabidiol    guidelines    impact    treatment    functional    interventions    anti    drugs    psychosocial    outcome    first    basis    cognitive    relapse    patients    schizophrenia    psychotic    prediction   

 Obiettivo del progetto (Objective)

'OPTiMiSE (OPtimization of Treatment and Management of Schizophrenia in Europe) will focus on two goals: optimising current treatments in Schizophrenia and explore novel therapeutic options for schizophrenia. The project intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new and experimental interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, will explore the development of novel treatments and will identify potential mechanisms for new drug development. To achieve these goals we have assembled a European team of experts that is second to none in the world. Together we will pursue the following objectives: -To use MRI to optimise treatment outcome and to facilitate prediction of response to treatment; - To provide a rational basis for antipsychotic choices in the treatment of first episode schizophrenia or schizophreniform disorder; - To improve functional outcome and reduce drug discontinuation by means of psychosocial interventions. - To explore the potential of cannabidiol CBD, a modulator of endocannabinoid functioning, as an alternative to D2 based antipsychotics - To validate a new approach to improve cognitive performance in patients with cognitive deficits on the basis of their genetic make up; - To use theoretically driven neurochemical imaging (MRS) and empirically driven genetic/genomic markers as predictors of response to treatment.'

Introduzione (Teaser)

A large European consortium is working to improve existing treatments for schizophrenia and implement new ones. Through clinical trials, the OPTIMISE study will determine treatment response, while novel imaging and biomarker tools will facilitate response prediction.

Descrizione progetto (Article)

The first drugs to treat schizophrenia were developed nearly 50 years ago and were designed to tackle the psychotic episodes of patients. Although in most instances these drugs have proved efficacious in treating psychosis, their overall functional impact is limited. As a result, patients suffer from cognitive deficits and those who discontinue the drugs quickly relapse.

In order to improve current treatment strategies, the EU-funded 'Optimization of treatment and management of schizophrenia in Europe' (http://www.optimisetrial.eu/ (OPTIMISE)) project will perform clinical trials. At the same time, it will test novel therapeutics in a series of experimental studies.

Treatment optimisation is based on concomitant examination of patients with magnetic resonance imaging (MRI) for the detection of any underlying pathological aetiology. The idea is that patients with pathophysiological causes should not receive anti-psychotic drugs. MRI, alongside proteomics and metabolomics markers, will also be used to assess how patients respond to treatment. Taken together, this information will determine the predictive role of MRI and molecular analysis.

An important part of OPTIMISE work is to provide evidence for the choice of anti-psychotic treatments. For this purpose, partners will evaluate if amilsulpride is a justified first-choice drug and what course of action should be taken for patients who fail to respond. Administration of clozapine will be assessed in this context.

In order to improve the functional outcome of existing treatments, the consortium will test the impact of various psychosocial interventions. Furthermore, novel therapeutic strategies such as cannabidiol will be evaluated. The trial protocols have been established and approved, and partners are in the process of recruiting patients.

The outcome of the OPTIMISE trials will significantly impact current diagnostic and therapeutic practice in schizophrenia. These evidence-based treatment guidelines are expected to improve treatment responses, while the psycho-educational package will improve adherence and prevent relapse.

Altri progetti dello stesso programma (FP7-HEALTH)

ACADEMIC GMP (2010)

The impact of Regulation (EC) No 1394/2007 on the development of Advanced Therapy Medicinal Products (ATMPs): an academic perspective

Read More  

EURIPFNET (2008)

"European IPF Network: Natural course, Pathomechanisms and Novel Treatment Options in Idiopathic Pulmonary Fibrosis"

Read More  

CANCERPATHWAYS (2008)

Developmental Molecular Pathways in Drosophila as a Model for Human Cancer

Read More